Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)

NCT04750629 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2021-06-18

No results posted yet for this study

Summary

Prospective study that will evaluate the clinical agreement of the CoviDx™ Rapid Antigen test compared to SARS-CoV-2 RT-PCR.

Conditions

Interventions

DEVICE

POC CoviDx™ Rapid Antigen Test

All patients will have a nasal swab for CoviDx™ Rapid Antigen testing

Sponsors & Collaborators

  • Rapid Pathogen Screening

    collaborator INDUSTRY
  • Lumos Diagnostics

    lead INDUSTRY

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-08
Primary Completion
2021-05-07
Completion
2021-05-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04750629 on ClinicalTrials.gov